



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/807,897	03/24/2004	Rong Xiang	TSR1 874.1	6550
<div>7590 OLSON & HIERL, LTD. 36th Floor 20 North Wacker Drive Chicago, IL 60606</div>				
<div>05/26/2009</div>				
<div>EXAMINER</div>				
<div>SHEN, WU CHENG WINSTON</div>				
<div>ART UNIT</div>		<div>PAPER NUMBER</div>		
<div>1632</div>				
<div>MAIL DATE</div>		<div>DELIVERY MODE</div>		
<div>05/26/2009</div>		<div>PAPER</div>		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/807,897

Applicant(s)

XIANG ET AL.

Examiner

WU-CHENG Winston SHEN

Art Unit

1632

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 24 February 2009.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1, 26, 28 and 53 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, 26, 28, and 53 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 03/24/2004 and 06/03/2004 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

1. A request for continued examination (RCE) under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 02/24/2009 has been entered.

Claims 2-25, 27, and 29-52 are cancelled. Claim 1 has been amended. Claims 1, 26, 28, and 53 are pending and currently under examination.

This application 10/807,897 filed on March 24, 2004 claims the benefit of 60/457,009 filed on 03/24/2003.

Claim Rejection - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

2. Previous rejection of claim 1 under 35 U.S.C. 103(a) as being unpatentable over **Rovero et al.** (Rovero et al. Insertion of the DNA for the 163-171 peptide of IL1 β enables a DNA vaccine encoding p185 (neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice. *Gene Ther.* 8(6): 447-52, 2001) in view of **Gordan et al.** (Gordan et al.

Universal tumor antigens as targets for immunotherapy, *Cytotherapy*, 4(4):317-27, 2002), **Nagira et al.** (Nagira et al., A lymphocyte-specific CC chemokine, secondary lymphoid tissue chemokine (SLC), is a highly efficient chemoattractant for B cells and activated T cells. *Eur J Immunol.* 28(5):1516-23, 1998), and **Lu et al.** (US 5,733,760, issued 03/31/1998), is *withdrawn* because the claim has been amended.

Claim 1 has been amended to recite additional limitation “wherein the DNA vaccine induces a cytotoxic T-lymphocyte immune response against tumor cells when orally administered to a patient”.

3. Previous rejection of claim 26 under 35 U.S.C. 103(a) as being unpatentable over **Rovero et al.** (Rovero et al. Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185 (neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice. *Gene Ther.* 8(6): 447-52, 2001) in view of **Gordan et al.** (Gordan et al. Universal tumor antigens as targets for immunotherapy, *Cytotherapy*, 4(4):317-27, 2002), **Nagira et al.** (Nigira et al., A lymphocyte-specific CC chemokine, secondary lymphoid tissue chemokine (SLC), is a highly efficient chemoattractant for B cells and activated T cells. *Eur J Immunol.* 28(5):1516-23, 1998), **Lu et al.** (US 5,733,760, issued 03/31/1998) as applied to claim 1 above, and further in view of **Bennett et al.** (Bennett et al. WO200157059-A1 and U.S. Patent No. 6,335,194, SEQ ID No: 10, columns 27, 53-55; this reference has been provided in the Non-Final office action mailed on 12/13/2006), is *withdrawn* because the claim has been amended.

Claim 1 has been amended to recite additional limitation “wherein the DNA vaccine induces a cytotoxic T-lymphocyte immune response against tumor cells when orally administered to a patient”. Claim 26 depends from claim 1.

4. Previous rejection of claim 28 under 35 U.S.C. 103(a) as being unpatentable over **Rovero et al.** (Rovero et al. Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185 (neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice. *Gene Ther.* 8(6): 447-52, 2001) in view of **Gordan et al.** (Gordan et al. Universal tumor antigens as targets for immunotherapy, *Cytotherapy*, 4(4):317-27, 2002), **Nagira et al.** (Nigira et al., A lymphocyte-specific CC chemokine, secondary lymphoid tissue chemokine (SLC), is a highly efficient chemoattractant for B cells and activated T cells. *Eur J Immunol.* 28(5):1516-23, 1998), **Lu et al.** (US 5,733,760, issued 03/31/1998) as applied to claim 1 above, and further in view of **Tanabe et al.** (Tanabe et al., direct submission, submitted to Genetics Institute, 87 Cambridge Park Drive, Cambridge, MA 02140, USA, on 03-JUN-1997, direct submission of DNA sequences of CCL21; this reference has been provided in the Non-Final office action mailed on 12/13/2006), is **withdrawn** because the claim has been amended.

Claim 1 has been amended to recite additional limitation “wherein the DNA vaccine induces a cytotoxic T-lymphocyte immune response against tumor cells when orally administered to a patient”. Claim 28 depends from claim 1.

5. Previous rejection of claim 53 under 35 U.S.C. 103(a) as being unpatentable over **Rovero et al.** (Rovero et al. Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA

vaccine encoding p185 (neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice. *Gene Ther.* 8(6): 447-52, 2001) in view of **Gordan et al.** (Gordan et al. Universal tumor antigens as targets for immunotherapy, *Cytotherapy*, 4(4):317-27, 2002), **Nagira et al.** (Nigira et al., A lymphocyte-specific CC chemokine, secondary lymphoid tissue chemokine (SLC), is a highly efficient chemoattractant for B cells and activated T cells. *Eur J Immunol.* 28(5):1516-23, 1998), **Lu et al.** (US 5,733,760, issued 03/31/1998) as applied to claim 1 above, and further in view of **Bennett et al.** (Bennett et al. WO200157059-A1 and U.S. Patent No. 6,335,194, SEQ ID No: 10, columns 27, 53-55; this reference has been provided in the Non-Final office action mailed on 12/13/2006), and **Tanabe et al.** (Tanabe et al., direct submission, submitted to Genetics Institute, 87 Cambridge Park Drive, Cambridge, MA 02140, USA, on 03-JUN-1997, direct submission of DNA sequences of CCL21; this reference has been provided in the Non-Final office action mailed on 12/13/2006), is *withdrawn* because the claim has been amended.

Claim 1 has been amended to recite additional limitation “wherein the DNA vaccine induces a cytotoxic T-lymphocyte immune response against tumor cells when orally administered to a patient”. Claim 53 depends from claim 1.

Applicant's arguments and Response to Applicant's arguments

Applicant's arguments regarding abovementioned withdrawn 103 rejections that are relevant to the following new 103 rejections are discussed in this section.

(i) Applicant argues that none of the references cited in withdrawn 103 rejections discloses the induction of significant cytotoxic T lymphocyte (CTL) response (See page 5 of Applicant's response filed on 1/22/2009).

In response, the new 103 rejections listed below citing Anderson et al., which discloses spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in breast cancer, leukemia, and melanoma patients both *in situ* as well as *ex vivo*

(ii) Applicant argues that regardless of whether or not a *prima facie* case for obviousness has been established, the present invention provides benefits and results that are unexpected and could not have been predicted based on the teachings of the prior art. For example, the data in Table 2, on page 35, clearly demonstrate a significant up-regulation of CD8 T-cells that express CD25, CD28 and CD69 activation markers, in comparison to examples involving only the survivin protein or only the CCL21. (See page 6 of Applicant's response filed on 1/22/2009).

Applicant argues that, as a further example, the data in Table 3, on page 42, clearly indicates a dramatic reduction in D121 Lewis lung tumor metastasis in mice vaccinated with the claimed vaccine relative to mice treated with a vaccine comprising survivin DNA alone or CCL21 DNA alone, i.e., 6 out of 8 mice treated with the claimed virus had metastasis scores of "0". The remaining mice had scores of "1", compared to the results from mice from the survivin or CCL21 treatment groups, in which the majority of mice had metastasis scores of "2" or "3". The prior art simply does not provide sufficient information for one of ordinary skill to have predicted these improvements demonstrated by the present invention. (See page 6 of Applicant's response filed on 1/22/2009).

In response, the data shown in Table 2 demonstrate the effect of muSurvivin/muCCL21 vaccine in up-regulation of CD8 T-cells that express CD25, CD28 and CD69 activation marker is higher than muSurvivin vaccine alone or muCCL21 alone. However, it is unclear why this data are unexpected because CCL21 is known to enhance CTL immune response specifically, which is discussed in the new 103 rejections below. Furthermore, it is worth noting that the effect of muSurvivin/muCCL21 vaccine is far lower than additive (not to mention synergistic) effects of muSurvivin vaccine alone and muCCL21 alone. It is not persuasive that the disclosed lower than additive effect is unexpected. With regard to data in Table 3 being unexpected, the Examiner notes again that CCL21 is known to enhance CTL immune response specifically. Therefore, it is not unexpected the effect of muSurvivin/muCCL21 vaccine on growth reduction of metastatic tumors is better than those effects of muSurvivin vaccine alone or muCCL21 alone. Accordingly, the arguments of unexpected results have been fully considered and found not persuasive.

The following rejections under 35 U.S.C. 103(a) are necessitated claim amendments filed on 01/22/2009.

6. Claim 1 under 35 U.S.C. 103(a) as being unpatentable over **Haupt et al.** (Haupt et al., The potential of DNA vaccination against tumor-associated antigens for antitumor therapy, *Exp Biol Med (Maywood)*. 227(4):227-37, 2002) in view of **Gordan et al.** (Gordan et al. Universal tumor antigens as targets for immunotherapy, *Cytotherapy*, 4(4):317-27, 2002; this reference has been cited in the office action mailed on 04/25/2008), **Andersen et al.** (Andersen

et al., Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients, *Cancer Res.* 61(16):5964-8, 2001), **Luther et al.** (Luther et al., Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis, *J Immunol.* 169(1):424-33, 2002; this reference has been cited in the office action mailed on 07/06/2007), and **Lu et al.** (US 5,733,760, issued 03/31/1998; this reference has been cited in the office action mailed on 04/25/2008).

Claim 1 reads as follows: A DNA vaccine suitable for eliciting an immune response against cancer cells comprising a DNA construct operably encoding at least one survivin protein and one CCL21 cytokine in a pharmaceutically acceptable carrier; wherein the DNA construct is incorporated in an attenuated *Salmonella typhimurium* vector that targets Peyer's patches in the gut, wherein the DNA vaccine induces a cytotoxic T-lymphocyte immune response against tumor cells when orally administered to a patient.

Haupt et al. teaches that by DNA vaccination, antigen-specific cellular as well as humoral immune responses can be generated. The induction of specific immune responses directed against antigens expressed in tumor cells and displayed e.g., by MHC class I complexes can inhibit tumor growth and lead to tumor rejection (See abstract, Figure 1, Haupt et al., 2002). A common strategy to further enhance DNA-based immunization is to employ cytokine genes as adjuvants. (See Table 1, and right column, page 230, Haupt et al., 2002) by linking the cytokine gene directly to the DNA vaccine or inserting DNA coding for an immunomodulatory peptide of a cytokine (See left column, page 231, Haupt et al., 2002). As an example, Haupt et al. discloses

that almost all of these carcinomas (i.e. a malignant tumor of epithelial origin) specifically express calcitonin, and calcitonin may represent a suitable target antigen for DNA vaccines. Haupt et al. shows that DNA immunization by gene gun with an expression plasmid encoding the human calcitonin precursor preprocalcitonin that enables induction of antigen-specific cellular and humoral immune responses in mice, and co-delivery of a plasmid encoding GM-CSF increases the efficacy of this DNA vaccine (See left column, page 233, Haupt et al., 2002).




Figure 1. Priming of immune responses against tumor cells by DNA vaccination. The direct inoculation of plasmid DNA encoding a tumor-associated antigen into host cells, including professional APC, leads to the *in vivo* synthesis of the encoded antigen. The intracellular protein is processed into peptides that associate with MHC class I molecules. The MHC class I-peptide complex is displayed on the cell surface where it can be recognized by CD8⁺ T cells. Once activated, CD8⁺ T cells acquire cytotoxic functions and can specifically lyse cells expressing the

target antigen. The predominant cell type capable of inducing T cells to become effector cells that can recognize and kill tumor cells following DNA immunization are bone marrow-derived APC. The CD28 molecule on the T cell membrane can interact with costimulatory molecules like B7-1 on APC. Lysis of transfected cells expressing the antigen or secretion of the antigen lead to the release of protein, which is taken up by APC. Internalized into lysosomes, the antigen is proteolytically degraded into peptides that associate with MHC class II molecules. The MHC class II-peptide complexes travel to the cell surface of APC where they can be recognized by CD4⁺ T cells. These cells secrete cytokines that may facilitate tumor cell destruction in the effector phase of immune responses following DNA vaccination. Tumor-specific CD4⁺ cells not only provide help for the induction of specific CD8⁺ CTL, but may also be critical in activating macrophages and eosinophils to produce nitric oxide and superoxides that participate in the destruction of tumor cells.

Haupt et al. does not teach (i) survivin as a tumor specific antigen, (ii) CCL21 as a cytokine that enhance T cell mediated immune response, or (iii) a DNA construct been incorporated in an attenuated *Salmonella typhimurium* vector that targets Peyer's patches in the gut.

However, at the time of filing of instant application, the art taught that (i) universal tumor antigens, including survivin, expressed in all tumors but not expressed in non-cancerous tissue, can be used as targets immunotherapy, and (ii) the tumor cell specific immune response can be enhanced by the presence of various cytokines (See, for instance, second paragraph, right column of page 118, Gordan et al., 2002). Furthermore, the advantages of a vaccine comprising attenuated *Salmonella typhimurium* as a vector to express exogenous antigen(s) that can be delivered orally for vaccination and targets Peyer's patches in the gut, are also known in the art.

Regarding survivin being a universal tumor associated antigens as targets for immunotherapy, **Gordan et al.** teaches that the cardinal feature of universal tumor associated antigen (TAA, also known as tumor specific antigen) is that they are expressed in nearly all tumors but not expressed in non-cancerous tissue, and they are directly involved in the

Art Unit: 1632

malignant phenotype of the tumor. Gordan et al. teaches that certain peptides derived from such Ags are expressed on the tumor-cell surface, as evidenced by Ag-specific, MHC-restricted T-cell anti-tumor reactivity. Gordan et al. also teaches that four examples (i.e. a definitive number) of universal tumor Ags (hTERT, CYP1B1, survivin, and MDM2; see left column page 321 and Table 1 page 3232), each at various levels of preclinical and clinical development. Gordan et al. further teaches that features of universal TAA indicate a pre-existing, high-affinity T-cell pool that can be activated *in vivo* in patients, without immunoselection of variant tumor cells no longer expressing the Ag of choice. (See summary of Results and Discussion, page 317, Gordan et al. Universal tumor antigens as targets for immunotherapy, *Cytotherapy*, 4(4):317-27, 2002). Consistent with the teachings of Gordan et al., **Andersen et al.** teaches that advances in therapeutic tumor vaccinations necessitate the identification of broadly expressed, immunogenic tumor antigens that are not prone to immune selection. To this end, the human inhibitor of apoptosis, survivin, is a prime candidate because it is expressed in most human neoplasms but not in normal, differentiated tissues. Anderson et al. demonstrates spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in breast cancer, leukemia, and melanoma patients both *in situ* as well as *ex vivo* (See abstract, Andersen et al., 2001).

Regarding CCL21/SLC (secondary lymphoid tissue chemokine) as a cytokine that specifically enhances T cell mediated immune response, **Luther et al.** teaches that a comparison of CCL19 transgenic mice with mice expressing CCL21 (secondary lymphoid tissue chemokine) revealed that CCL21 induced larger and more organized infiltrates, and a more significant role for CCL21 is also suggested in lymphoid tissues, as CCL21 protein was found to be present in

lymph nodes and spleen at much higher concentrations than CCL19 (See abstract, Luther et al., 2002). Luther et al. teaches that a striking feature of the infiltrates in RIP-CCL21 transgenic mice was the localization of DCs and T cells, but not B cells, close to the chemokine-expressing islet cells., which is exactly the opposing pattern has been previously observed in RIP-CXCL13 transgenic mice, where B cells line the islets and T cells are localized more distantly (See second paragraph, left column, page 426, Luther et al., 2002).

Regarding the limitation "DNA construct is incorporated in an attenuated *Salmonella typhimurium* vector that targets Peyer's patches in the gut", **Lu et al.** (1998) teaches the following: Attenuated *Salmonella typhimurium* has been proposed as one means of providing effective delivery of desired antigens. They provide the advantage that they can be delivered orally. The bacteria grow rapidly and do not require growth in cell culture. Thus, large scale production of vectors, for example, in the use of vaccines, can be accomplished more quickly and easy then where mammalian tissue cultures are required. After oral ingestion, *Salmonella* are concentrated within the liver, spleen, bone marrow, and the Peyers' patches of the gut-associated lymphoid tissue (GALT) (See Abstract, and lines 39-54, column 1, Lu et al., 1998).

Therefore, it would have been *prima facie* obvious to one having ordinary skill in the art at the time of the invention to generate a DNA vaccine construct to be incorporated into and orally delivered by *Salmonella* vector, as taught by Lu et al (1998), via combined teachings of (i) Haupt et al regarding the induction of specific immune responses directed against antigens expressed in tumor cells and displayed e.g., by MHC class I complexes via DNA vaccination of tumor specific antigen and cytokine, (ii) Gordan et al. regarding survivin is one of four of universal tumor Ags (hTERT, CYP1B1, survivin, and MDM2), and Andersen et al. regarding

spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in breast cancer, leukemia, and melanoma patients both *in situ* as well as *ex vivo*, and (iii) Luther et al. regarding cytokine CCL21 specifically enhances T cell mediated immune response, to arrive at the claimed DNA vaccine that induces a cytotoxic T lymphocyte immune response against tumor cells when orally administering *Salmonella typhimurium* comprising the DNA vaccine to a patient.

One having ordinary skill in the art would have been motivated to combine the teachings of Haupt et al. (2002) in view of Gordan et al. (2002), Andersen et al. (2001), Luther et al. (2002), and Lu et al. (1998) to achieve at a DNA vaccine that induces a cytotoxic T lymphocyte immune response against all tumors because (i) Haupt et al. teaches a DNA vaccine that induces cytotoxic T lymphocyte immune response by expressing various tumor associated antigens (TAAs), which are present in various tumors (i.e. non-universal TAA), and the effect of expression of cytokine in enhancing the efficacy of the DNA vaccine, (ii) Gordan et al. teaches survivin is one of four established universal tumor Ags (hTERT, CYP1B1, survivin, and MDM2), and Andersen et al. regarding spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in breast cancer, leukemia, and melanoma patients both *in situ* as well as *ex vivo*, (iii) Luther et al. teaches cytokine CCL21, not cytokine CCL19, specifically enhances T cell mediated immune response, and (iv) Lu et al. teaches that the advantage of using *Salmonella typhimurium* comprising the DNA vaccine as a vehicle for targeted delivery of antigen to Peyer's patches in the gut via oral delivery of *S. typhimurium*

There would have been a reasonable expectation of success given (i) successful demonstration of DNA vaccine delivered by gene gun with an expression plasmid encoding the

human calcitonin precursor preprocalcitonin enables induction of antigen-specific cellular and humoral immune responses in mice, and co-delivery of a plasmid encoding GM-CSF increased the efficacy of this DNA vaccine, by the teachings of Haupt et al., (ii) successful identification and validation of survivin as one of four universal tumor associated antigens, by the teachings of Gordan et al., and demonstration of spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in breast cancer, leukemia, and melanoma patients both *in situ* as well as *ex vivo*, by the teachings of Andersen et al., and (iii) successful demonstration of the effect of CCL21 in specifically increasing T cell mediated cytolytic response, by the teachings of Luther et al., and (iv) successful generation of attenuated *Salmonella typhimurium* that can express exogenous antigens and the demonstration of using attenuated *Salmonella typhimurium* for oral vaccination, by the teachings of Lu et al., 1998.

Thus, the claimed invention as a whole was clearly *prima facie* obvious.

7. Claim 26 is rejected under 35 U.S.C. 103(a) as being unpatentable over **Haupt et al.** (Haupt et al., The potential of DNA vaccination against tumor-associated antigens for antitumor therapy, *Exp Biol Med (Maywood)*. 227(4):227-37, 2002) in view of **Gordan et al.** (Gordan et al. Universal tumor antigens as targets for immunotherapy, *Cytotherapy*, 4(4):317-27, 2002; this reference has been cited in the office action mailed on 04/25/2008), **Andersen et al.** (Andersen et al., Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients, *Cancer Res.* 61(16):5964-8, 2001), **Luther et al.** (Luther et al., Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis, *J Immunol.*

169(1):424-33, 2002; this reference has been cited in the office action mailed on 07/06/2007), and **Lu et al.** (US 5,733,760, issued 03/31/1998; this reference has been cited in the office action mailed on 04/25/2008), as applied to claim 1 above, and further in view of **Bennett et al.** (Bennett et al. WO200157059-A1 and U.S. Patent No. 6,335,194, SEQ ID No: 10, columns 27, 53-55; this reference has been provided in the Non-Final office action mailed on 12/13/2006).

The teachings of Haupt et al., Gordan et al., Andersen et al., Luther et al., and Lu et al. have been discussed in the preceding section of the rejection of claim 1 under 35 U.S.C. 103(a) as being unpatentable over Haupt et al. (2002) in view of Gordan et al. (2002), Andersen et al. (2001), Luther et al. (2002), and Lu et al. (1998).

None of Haupt et al., Gordan et al., Andersen et al., Luther et al., and Lu et al. teaches SEQ ID No: 3 recited in claim 26.

However, at the time of filing of instant application, the DNA construct encoding a murine survivin protein comprising SEQ ID No. 3 recited in claim 26, was known in the art. For instant, **Bennett et al.** teach DNA encoding mouse survivin that identical to SEQ ID NO: 3 (See Bennett et al. WO200157059-A1 and U.S. Patent No. 6,335,194, SEQ ID No: 10, columns 27, 53-55, detailed alignment of sequences listed below)

RESULT 1

AAS21530

ID AAS21530 standard; cDNA; 955 BP.

XX

AC AAS21530;

XX

DT 21-NOV-2001 (first entry)

XX

DE DNA encoding mouse survivin.

XX

KW Survivin; human; mouse; cytostatic; antisense oligonucleotide;
hyperproliferative condition; cancer; apoptosis; cytokinesis; ss.

XX

OS Mus musculus.

XX

PN WO200157059-A1.

XX

PD 09-AUG-2001.

Art Unit: 1632

XX 30-JAN-2001; 2001WO-US002939.
 XX
 XX 02-FEB-2000; 2000US-00496694.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Bennett CF, Ackermann BJ, Swayze EE, Cowser LM;
 XX
 XX WFI; 2001-488863/53.
 XX
 XX Novel antisense compounds for modulating the expression of Survivin and
 XX treatment of cancer.
 XX
 XX Example 13; Page 80-81; 120pp; English.
 XX
 XX
 XX The invention relates to antisense oligonucleotides targeted to a nucleic
 XX acid molecule encoding human Survivin, where the antisense
 XX oligonucleotide inhibits the expression of human Survivin. These
 XX antisense oligonucleotides are used in the treatment of an animal
 XX suffering from a disease or condition associated with Survivin, e.g. a
 XX hyperproliferative condition such as cancer, and comprises administering
 XX a therapeutically or prophylactically effective amount of the antisense
 XX oligonucleotide so that expression of Survivin is inhibited. The
 XX oligonucleotides can also be used to treat a human suffering from a
 XX disease or condition characterised by a reduction in apoptosis comprising
 XX administering the antisense oligonucleotide to a human. In addition, the
 XX antisense oligonucleotide and a cytotoxic chemotherapeutic agent e.g.
 XX taxol or cisplatin, can be used to modulate apoptosis, cytokinesis or the
 XX cell cycle, or inhibit the proliferation in a cancer cell by contacting
 XX the cell with the antisense oligonucleotide. AAS21521-AAS21768 represent
 XX Survivin nucleic acids, and antisense oligonucleotides targeted to
 XX Survivin, used in the method of the invention
 XX
 XX Sequence 955 BP; 230 A; 227 C; 265 G; 233 T; 0 U; 0 Other;

Query Match 100.0%; Score 955; DB 5; Length 955;
 Best Local Similarity 100.0%; Pred. No. 3.6e-284;
 Matches 955; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy	1	GGCAGAGGGGGCCGGGGCTCTCCGGCATGCTCTGGGCGCGGCTCCGCCCGCGGATT	60
Db	1	GGCAGAGGGGGCCGGGGCTCTCCGGCATGCTCTGGGCGCGGCTCCGCCCGCGGATT	60
Qy	61	TGAATCCTGCGTTTGAAGTCTCTTGGCGGAGGTTGTGTGACGCCATCATGGGAGCTCCG	120
Db	61	TGAATCCTGCGTTTGAAGTCTCTTGGCGGAGGTTGTGTGACGCCATCATGGGAGCTCCG	120
Qy	121	GGGCTGCCCCAGATCTGGCAGCTGTGATCTCAAGAACTACCGCATCGCCACCTTCAAGAAC	180
Db	121	GGGCTGCCCCAGATCTGGCAGCTGTGATCTCAAGAACTACCGCATCGCCACCTTCAAGAAC	180
Qy	181	TGGCCCTTCTGAGGAGCTGCGGCTGCAACCCAGAGCGAATGGCGAGGCTGGCTTCATC	240
Db	181	TGGCCCTTCTGAGGAGCTGCGGCTGCAACCCAGAGCGAATGGCGAGGCTGGCTTCATC	240
Qy	241	CAGTCCCTACCGAGAACGAGCCGTGATTGGCCCGAGTGTTTTTCTGCTTTAAGGAATTG	300
Db	241	CAGTCCCTACCGAGAACGAGCCGTGATTGGCCCGAGTGTTTTTCTGCTTTAAGGAATTG	300
Qy	301	GAAGGCTGGGAACCCGATGACAAACCGATAGAGAGCATAGAAAGCACTCCCTGGCTGC	360
Db	301	GAAGGCTGGGAACCCGATGACAAACCGATAGAGAGCATAGAAAGCACTCCCTGGCTGC	360
Qy	361	GCCTTCTCACTGTCAAGAAGCAGATGGGAAGAACTAACCGTCAGTGAATCTTGAAGACTG	420
Db	361	GCCTTCTCACTGTCAAGAAGCAGATGGGAAGAACTAACCGTCAGTGAATCTTGAAGACTG	420

```
Qy      421  GACAGACAGAGAGCCAAAGAACAAAATTGCCAAGGAGACCAACAACAGCAAAAAGAGTTT  480
Db      421  GACAGACAGAGAGCCAAAGAACAAAATTGCCAAGGAGACCAACAACAGCAAAAAGAGTTT  480

Qy      481  GAAGAGACTGCAAAAGACTACCCGTCAGTCAATTGAGCAGCTGGCTGCTTAATGCTGAGGC  540
Db      481  GAAGAGACTGCAAAAGACTACCCGTCAGTCAATTGAGCAGCTGGCTGCTTAATGCTGAGGC  540

Qy      541  TTTGCTGAGATAACTTTGGACCTGAGTGACATGCCACATCTAAGCCACGGCATCCACGCTTT  600
Db      541  TTTGCTGAGATAACTTTGGACCTGAGTGACATGCCACATCTAAGCCACGGCATCCACGCTTT  600

Qy      601  TCCAGCCAGGGCCTCCTAGCAGGATCTTAGAGAAGGAGACAGTGGTATTTTGAAACTGGA  660
Db      601  TCCAGCCAGGGCCTCCTAGCAGGATCTTAGAGAAGGAGACAGTGGTATTTTGAAACTGGA  660

Qy      661  TATCAAAATATTTTTGGTTTTGCTTTAAAGTGGCTACCTCTCTTTGGTTTTTGGGCTTTGC  720
Db      661  TATCAAAATATTTTTGGTTTTGCTTTAAAGTGGCTACCTCTCTTTGGTTTTTGGGCTTTGC  720

Qy      721  TCTATTGTGACGTGGACTTAAGCAATAAGGAAGTGATGAAGGGACAGTGTCTCTGACAG  780
Db      721  TCTATTGTGACGTGGACTTAAGCAATAAGGAAGTGATGAAGGGACAGTGTCTCTGACAG  780

Qy      781  GACCTGTGGGGGTCGGGGTGCCGTGTGCAAGGTCCTTGGTTCTGATTGTGATATTCCATAC  840
Db      781  GACCTGTGGGGGTCGGGGTGCCGTGTGCAAGGTCCTTGGTTCTGATTGTGATATTCCATAC  840

Qy      841  AGGGCTGCTAATGCAGCCCATGGGTAAGTGTGGTTATATGTGTTTGTGCTGATAAATTTG  900
Db      841  AGGGCTGCTAATGCAGCCCATGGGTAAGTGTGGTTATATGTGTTTGTGCTGATAAATTTG  900

Qy      901  TCCGTGATGAGTTTTCCTACCAAGGGGTAAAGGAATAAAAAACACTTGAAAAAGTGG  955
Db      901  TCCGTGATGAGTTTTCCTACCAAGGGGTAAAGGAATAAAAAACACTTGAAAAAGTGG  955
```

Therefore, it would have been *prima facie* obvious to one having ordinary skill in the art at the time of the invention to incorporate the teachings of Bennett et al. on the DNA encoding mouse survivin, which is identical to SEQ ID NO: 3 recited in claim 26 of instant application, into the combined teachings of Haupt et al., Gordan et al., Andersen et al., Luther et al., and Lu et al. directing to a DNA vaccine suitable for eliciting a CTL immune response against cancer cells comprising a DNA construct operably encoding at least one survivin protein and at least one CCL21 cytokine in a pharmaceutically acceptable carrier; wherein the DNA construct is incorporated in an attenuated *Salmonella typhimurium* vector that targets Peyer's patches in the gut of a patient when the patient is orally vaccinated with the DNA construct.

One having ordinary skill in the art would have been motivated to incorporate the teachings of Bennett et al. on the DNA encoding mouse survivin, which is identical to SEQ ID NO: 3 recited in claim 26 of instant application, into the combined teachings of Haupt et al., Gordan et al., Andersen et al., Luther et al., and Lu et al. because survivin is conserved in mammals, universally expressed in tumor cells but not in other normal tissues, and SEQ ID No: 3 encodes mouse survivin.

There would have been a reasonable expectation of success given (i) successful demonstration of DNA vaccine delivered by gene gun with an expression plasmid encoding the human calcitonin precursor preprocalcitonin enables induction of antigen-specific cellular and humoral immune responses in mice, and co-delivery of a plasmid encoding GM-CSF increased the efficacy of this DNA vaccine, by the teachings of Haupt et al., (ii) successful identification and validation of survivin as one of four universal tumor associated antigens, by the teachings of Gordan et al. and demonstration of spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in breast cancer, leukemia, and melanoma patients both *in situ* as well as *ex vivo*, by the teachings of Andersen et al., and (iii) successful demonstration of the effect of CCL21 in specifically increasing T cell mediated cytolytic response, by the teachings of Luther et al., and (iv) successful generation of attenuated *Salmonella typhimurium* that can express exogenous antigens and the demonstration of using attenuated *Salmonella typhimurium* for oral vaccination, by the teachings of Lu et al., 1998, and (v) DNA encoding mouse survivin was readily available.

Thus, the claimed invention as a whole was clearly *prima facie* obvious.

8. Claim 28 is rejected under 35 U.S.C. 103(a) as being unpatentable over **Haupt et al.** (Haupt et al., The potential of DNA vaccination against tumor-associated antigens for antitumor therapy, *Exp Biol Med* (Maywood). 227(4):227-37, 2002) in view of **Gordan et al.** (Gordan et al. Universal tumor antigens as targets for immunotherapy, *Cytotherapy*, 4(4):317-27, 2002; this reference has been cited in the office action mailed on 04/25/2008), **Andersen et al.** (Andersen et al., Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients, *Cancer Res.* 61(16):5964-8, 2001), **Luther et al.** (Luther et al., Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis, *J Immunol.* 169(1):424-33, 2002; this reference has been cited in the office action mailed on 07/06/2007), and **Lu et al.** (US 5,733,760, issued 03/31/1998; this reference has been cited in the office action mailed on 04/25/2008), as applied to claim 1 above, and further in view of **Tanabe et al.** (Tanabe et al., direct submission, submitted to Genetics Institute, 87 Cambridge Park Drive, Cambridge, MA 02140, USA, on 03-JUN-1997, direct submission of DNA sequences of CCL21; this reference has been provided in the Non-Final office action mailed on 12/13/2006).

The teachings of Haupt et al., Gordan et al., Andersen et al., Luther et al., and Lu et al. have been discussed in the preceding section of the rejection of claim 1 under 35 U.S.C. 103(a) as being unpatentable over Haupt et al. (2002) in view of Gordan et al. (2002), Andersen et al. (2001), Luther et al. (2002), and Lu et al. (1998).

None of Haupt et al., Gordan et al., Andersen et al., Luther et al., and Lu et al. teaches SEQ ID No:7 recited in claim 28.

However, at the time of filing of instant application, the DNA construct encoding a murine survivin protein comprising SEQ ID No. 7 recited in claim 28, was known in the art. For instant, Tanabe et al. teach DNA encoding mouse CCL21 that is identical SEQ ID NO: 7 (Tanabe et al., direct submission, submitted to Genetics Institute, 87 Cambridge Park Drive, Cambridge, MA 02140, USA, on 03-JUN-1997, detailed alignment of sequences listed below; this reference has been provided in the Non-Final office action mailed on 12/13/2006).

```
RESULT 1
AF006637
LOCUS           AF006637                615 bp    mRNA    linear    ROD 22-JUN-1997
DEFINITION     Mus musculus beta-chemokine TCA4 mRNA, complete cds.
ACCESSION      AF006637
VERSION        AF006637.1   GI:2209188
KEYWORDS       .
SOURCE         Mus musculus (house mouse)
  ORGANISM     Mus musculus
    Eukaryota; Metazoa; Chordata; Cranista; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia;
    Sciurognathi; Muroidea; Muridae; Murinae; Mus.
REFERENCE      1 (bases 1 to 615)
  AUTHORS      Tanabe,S., Lu,Z., Luo,Y., Quackenbush,E.J., Berman,M.A.,
    Collins-Racie,L.A., Mi,S., Reilly,C., Lo,D., Jacobs,K.A. and
    Dorf,M.E.
  TITLE        Direct Submission
  JOURNAL      Submitted (03-JUN-1997) Genetics Institute, 87 Cambridge Park
    Drive, Cambridge, MA 02140, USA
FEATURES       Location/Qualifiers
  source       1..615
               /organism="Mus musculus"
               /mol_type="mRNA"
               /db_xref="taxon:10090"
               /tissue_type="thymus"
               /dev_stage="adult"
               /note="beta-chemokine"
               /codon_start=1
               /product="TCA4"
               /protein_id="AAB61440.1"
               /db_xref="GI:2209188"
               /translation="MAQMMTLSLLSLVLAICIPWTQSSDGGGGQDCLKYSQKKI PYSI
  CDS           VRGYRKQEP SLGCP IAILFSPRKHSKPELCANFEEGWVQNLMRRLDPPAPGKQSPG
               CRKNRGTSKSGKKGRGSKGCKRTEQTQPSRG"
ORIGIN
Query Match      100.0%; Score 615; DB 6; Length 615;
Best Local Similarity 100.0%; Pred. No. 3e-193;
Matches 615; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1  GAATTGCGCCAAAGAGGSCCTACGGCCAAAGAGGGCTAAACTTGGCGGCTGTCCATCTCAC 60
      |
Db      1  GAATTGCGCCAAAGAGGSCCTACGGCCAAAGAGGGCTAAACTTGGCGGCTGTCCATCTCAC 60

Qy      61  TACAGCTCTGGTCTCTCATCTCTCAACTCAACCAACAATCATGGCTCAGATGATGACTCTGAGC 120
      |
Db      61  TACAGCTCTGGTCTCTCATCTCTCAACTCAACCAACAATCATGGCTCAGATGATGACTCTGAGC 120
```

```
Qy      121  CTCCTTAGCCTGGTCTGCTCTCTGCATCCCTGGACCCAAGGCAGTGTATGGAGGGGGT 180
Db      121  CTCCTTAGCCTGGTCTGCTCTCTGCATCCCTGGACCCAAGGCAGTGTATGGAGGGGGT 180

Qy      181  CAGGACTGCTGCCCTTAAGTACAGCCAGAAAGAAAATTCCTACAGTATTGTCCGAGGCTAT 240
Db      181  CAGGACTGCTGCCCTTAAGTACAGCCAGAAAGAAAATTCCTACAGTATTGTCCGAGGCTAT 240

Qy      241  AGGAAGCAAGAACCAAGTTTAGGCTGTCCCATCCCGCAATCCTGTTCTCACCCCGGAAG 300
Db      241  AGGAAGCAAGAACCAAGTTTAGGCTGTCCCATCCCGCAATCCTGTTCTCACCCCGGAAG 300

Qy      301  CACTCTAAGCCTGAGCTATGTGCAAAACCTGAGGAAGGCTGGTGCAGAACCTGATGCC 360
Db      301  CACTCTAAGCCTGAGCTATGTGCAAAACCTGAGGAAGGCTGGTGCAGAACCTGATGCC 360

Qy      361  CGCCTGAGCCAGCCTCCAGCCCCAGGGAACAAGCCCCGGCTGCAGGAAGAACCGGGA 420
Db      361  CGCCTGAGCCAGCCTCCAGCCCCAGGGAACAAGCCCCGGCTGCAGGAAGAACCGGGA 420

Qy      421  ACCTCTAAGTCTGGAAGAAGGAAGGGCTCCAAAGGGCTGCAAGAGAACTGAACAGACA 480
Db      421  ACCTCTAAGTCTGGAAGAAGGAAGGGCTCCAAAGGGCTGCAAGAGAACTGAACAGACA 480

Qy      481  CAGCCCTCAAGAGGATAGCCAGTAGCCCGCTGGAGCCCAAGGAGATCCCCCAAGAACTT 540
Db      481  CAGCCCTCAAGAGGATAGCCAGTAGCCCGCTGGAGCCCAAGGAGATCCCCCAAGAACTT 540

Qy      541  CAAGCTGGGTGGTTACGGTCCAACTCACAGSCAAAGAGGGAGCTAGAAAAACAGACTCAG 600
Db      541  CAAGCTGGGTGGTTACGGTCCAACTCACAGSCAAAGAGGGAGCTAGAAAAACAGACTCAG 600

Qy      601  GAGCCGCTAGTCGAG 615
Db      601  GAGCCGCTAGTCGAG 615
```

Therefore, it would have been *prima facie* obvious to one having ordinary skill in the art at the time of the invention to incorporate the teachings of Tanabe et al. on the DNA encoding mouse survivin, which is identical to SEQ ID NO: 7 recited in claim 28 of instant application, into the combined teachings of Haupt et al., Gordan et al., Anderson et al., Luther et al., and Lu directing to a DNA vaccine suitable for eliciting a CTL immune response against cancer cells comprising a DNA construct operably encoding at least one survivin protein and at least one CCL21 cytokine in a pharmaceutically acceptable carrier; wherein the DNA construct is incorporated in an attenuated *Salmonella typhimurium* vector that targets Peyer's patches in the gut of a patient when the patient is orally vaccinated with the DNA construct.

One having ordinary skill in the art would have been motivated to incorporate the teachings of Tanabe et al. on the DNA encoding mouse survivin, which is identical to SEQ ID NO: 7 recited in claim 28 of instant application, into the combined teachings of Haupt et al., Gordan et al., Andersen et al., Luther et al., and Lu et al. because cytokine CCL21 is known to specifically enhance T cell mediated immune response, and SEQ ID No: 7 encodes mouse CCL21.

There would have been a reasonable expectation of success given (i) successful demonstration of DNA vaccine delivered by gene gun with an expression plasmid encoding the human calcitonin precursor preprocalcitonin enables induction of antigen-specific cellular and humoral immune responses in mice, and co-delivery of a plasmid encoding GM-CSF increased the efficacy of this DNA vaccine, by the teachings of Haupt et al., (ii) successful identification and validation of survivin as one of four universal tumor associated antigens, by the teachings of Gordan et al. and demonstration of spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in breast cancer, leukemia, and melanoma patients both *in situ* as well as *ex vivo*, by the teachings of Andersen et al., and (iii) successful demonstration of the effect of CCL21 in specifically increasing T cell mediated cytolytic response, by the teachings of Luther et al., and (iv) successful generation of attenuated *Salmonella typhimurium* that can express exogenous antigens and the demonstration of using attenuated *Salmonella typhimurium* for oral vaccination, by the teachings of Lu et al., 1998, and (v) DNA encoding mouse CCL21 was readily available.

Thus, the claimed invention as a whole was clearly *prima facie* obvious.

9. Claim 53 is rejected under 35 U.S.C. 103(a) as being unpatentable over **Haupt et al.** (Haupt et al., The potential of DNA vaccination against tumor-associated antigens for antitumor therapy, *Exp Biol Med (Maywood)*, 227(4):227-37, 2002) in view of **Gordan et al.** (Gordan et al. Universal tumor antigens as targets for immunotherapy, *Cytotherapy*, 4(4):317-27, 2002; this reference has been cited in the office action mailed on 04/25/2008), **Andersen et al.** (Andersen et al., Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients, *Cancer Res.* 61(16):5964-8, 2001), **Luther et al.** (Luther et al., Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis, *J Immunol.* 169(1):424-33, 2002; this reference has been cited in the office action mailed on 07/06/2007), and **Lu et al.** (US 5,733,760, issued 03/31/1998; this reference has been cited in the office action mailed on 04/25/2008), as applied to claim 1 above, and further in view of **Bennett et al.** (Bennett et al. WO200157059-A1 and U.S. Patent No. 6,335,194, SEQ ID No: 10, columns 27, 53-55; this reference has been provided in the Non-Final office action mailed on 12/13/2006), and **Tanabe et al.** (Tanabe et al., direct submission, submitted to Genetics Institute, 87 Cambridge Park Drive, Cambridge, MA 02140, USA, on 03-JUN-1997, direct submission of DNA sequences of CCL21; this reference has been provided in the Non-Final office action mailed on 12/13/2006).

The teachings of Haupt et al., Gordan et al., Andersen et al., Luther et al., and Lu et al. have been discussed in the preceding section of the rejection of claim 1 under 35 U.S.C. 103(a) as being unpatentable over Haupt et al. (2002) in view of Gordan et al. (2002), Andersen et al. (2001), Luther et al. (2002), and Lu et al. (1998).

None of Haupt et al., Gordan et al., Andersen et al., Luther et al., and Lu et al. teaches SEQ ID No:3 and SEQ ID No: 7 recited in claim 53.

However, at the time of filing of instant application, the DNA construct encoding a murine survivin protein comprising SEQ ID No. 3, the DNA construct encoding mouse CCL21 comprising SEQ ID No: 7, recited in claim 53, were known in the art. For instant, Bennett et al. teach DNA encoding mouse survivin that identical to SEQ ID NO: 3 (See Bennett et al. WO200157059-A1 and U.S. Patent No. 6,335,194, SEQ ID No: 10, columns 27, 53-55, see detailed alignment of sequences listed in the preceding rejection #7), and Tanabe et al. teach DNA encoding mouse CCL21 that is identical SEQ ID NO: 7 (Tanabe et al., direct submission, submitted to Genetics Institute, 87 Cambridge Park Drive, Cambridge, MA 02140, USA, on 03-JUN-1997, detailed alignment of sequences listed in the preceding rejection #8)

Therefore, it would have been *prima facie* obvious to one having ordinary skill in the art at the time of the invention to incorporate the teachings of Bennett et al. on the DNA encoding mouse survivin, which is identical to SEQ ID NO: 3, and the teachings of Tanabe et al. on the DNA encoding mouse CCL21, which is identical to SEQ ID NO: 7, as recited in claim 53 of instant application, into the combined teachings of Haupt et al., Gordan et al., Andersen et al., Luther et al., and Lu et al., directing to a DNA vaccine suitable for eliciting a CTL immune response against cancer cells comprising a DNA construct operably encoding at least one survivin protein and at least one CCL21 cytokine in a pharmaceutically acceptable carrier; wherein the DNA construct is incorporated in an attenuated *Salmonella typhimurium* vector that targets Peyer's patches in the gut of a patient when the patient is orally vaccinated with the DNA construct.

One having ordinary skill in the art would have been motivated to incorporate the teachings of Bennett et al. on the DNA encoding mouse survivin, which is identical to SEQ ID NO: 3, and the teachings of Tanabe et al. on the DNA encoding mouse CCL21, which is identical to SEQ ID NO: 7, as recited in claim 53 of instant application, into the combined teachings of Haupt et al., Gordan et al., Andersen et al., Luther et al., and Lu et al. because (i) survivin is conserved in mammals, universally expressed in tumor cells but not in other normal tissues, and SEQ ID No: 3 encodes mouse survivin, and (ii) cytokine CCL21 is known to specifically enhance T cell mediated immune response, and SEQ ID No: 7 encodes mouse CCL21.

There would have been a reasonable expectation of success given (i) successful demonstration of DNA vaccine delivered by gene gun with an expression plasmid encoding the human calcitonin precursor preprocalcitonin enables induction of antigen-specific cellular and humoral immune responses in mice, and co-delivery of a plasmid encoding GM-CSF increased the efficacy of this DNA vaccine, by the teachings of Haupt et al., (ii) successful identification and validation of survivin as one of four universal tumor associated antigens, by the teachings of Gordan et al. and demonstration of spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in breast cancer, leukemia, and melanoma patients both *in situ* as well as *ex vivo*, by the teachings of Andersen et al., and (iii) successful demonstration of the effect of CCL21 in specifically increasing T cell mediated cytolytic response, by the teachings of Luther et al., and (iv) successful generation of attenuated *Salmonella typhimurium* that can express exogenous antigens and the demonstration of using attenuated *Salmonella typhimurium* for oral vaccination, by the teachings of Lu et al., 1998, and

(v) DNA construct encoding mouse survivin and DNA construct encoding mouse CCL21 were readily available.

Thus, the claimed invention as a whole was clearly *prima facie* obvious.

Conclusion

10. No claim is allowed.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication from the examiner should be directed to Wu-Cheng Winston Shen whose telephone number is (571) 272-3157 and Fax number is 571-273-3157. The examiner can normally be reached on Monday through Friday from 8:00 AM to 4:30 PM. If attempts to reach the examiner by telephone are unsuccessful, the supervisory patent examiner, Peter Paras, Jr. can be reached on (571) 272-4517. The fax number for TC 1600 is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private

Art Unit: 1632

PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Wu-Cheng Winston Shen/

Patent Examiner

Art Unit 1632